Imaging in prostate cancer staging: Present role and future perspectives

Urologia Internationalis

Volumn 88, Issue 2, 2012, Pages 125-136

  Pinto, Francesco ^a   Totaro, Angelo ^a   Palermo, Giuseppe ^a   Calarco, Alessandro ^a   Sacco, Emilio ^a   D'Addessi, Alessandro ^a   Racioppi, Marco ^a   Valentini, Annalia ^a   Gui, Benedetta ^a   Bassi, Pierfrancesco ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Diffusion weighted MRI; Dynamic contrast enhanced MRI; Magnetic resonance spectroscopy; MRI; Positron emission tomography; Prostate cancer; Prostate ultrasonography imaging; Staging

Indexed keywords

BONE METASTASIS; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; HUMAN; LYMPH NODE METASTASIS; MOLECULAR IMAGING; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT RESPONSE;

BONE NEOPLASMS; DIAGNOSTIC IMAGING; DIFFUSION MAGNETIC RESONANCE IMAGING; EVIDENCE-BASED MEDICINE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATIC NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84859435770     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000335205     Document Type: Review

References (131)

1. Farlay J, Parkin DM, Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-781.
2. SEER Stat Fact Sheets: prostate. Available at http://seer.cancer.gov/ statfacts/html/prost. html 2010.
3. Hanley JA: Mortality reductions produced by sustained prostate cancer screening have been understimated. J Med Screen 2010; 17: 147-151.
4. Silverberg E, Boring CC, Squires TS: Cancer statistics, 1990. CA Cancer J Clin 1990; 40: 9-26.
5. Jemal A, Murray T, Ward E, et al: Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30; published correction in CA Cancer J Clin 2005; 55: 259. (Pubitemid 40310185)
6. Soh S, Kattan MW, Berkman S, Wheeler TM, Scardino PT: Has there been a recent shift in the pathological features and prognosis of patients with radical prostatectomy? J Urol 1997 157 2212-2218. (Pubitemid 27208674)
7. Lindner U, Trachtenberg J, Lawrentschuk N: Focal therapy in prostate cancer: modalities, findings and future considerations. Nat Rev Urol 2010; 7: 562-571.
8. Cooperberg MR, Lubeck DP, Grossfeld GD, Mehta SS, Carroll PR: Contemporary trends in imaging test utilization for prostate cancer staging: data from the cancer of the prostate strategic urologic research endeavor. J Urol 2002; 168: 491-495. (Pubitemid 34793279)
9. Turkbey B, Albert PS, Kurdzie K, Choyke P: Imaging localized prostate cancer: current approaches and new developments. AJR Am J Roentgenol 2009; 192: 1471-1480
10. Green FL, Page DL, Fleming ID, et al: AJCC cancer staging manual. New York, Springer, 2002.
11. Amis ES Jr, Bigongiari LR, Bluth EI, et al: Pretreatment staging of clinically localized prostate cancer. Radiology 2000; 215: 703-708.
12. Carroll P, Coley C, McLeod D, et al: Prostatespecific antigen best practice policy. II. Prostate cancer staging and post-treatment follow-up. Urology 2001; 57: 225-229. (Pubitemid 32140793)
13. Ukimura O, Troncoso P, Ramirez EI, et al: Prostate cancer staging: correlation between ultrasound determined tumor contact length and pathologically confirmed extraprostatic extension. J Urol 1998; 159: 1251-1259. (Pubitemid 28172808)
14. Ravizzini G, Turkbey B, Kurdziel K, Choyke PL: New horizons in prostate cancer imaging. Eur J Radiol 2009; 70: 212-226.
15. Ohori M, Egawa S, Shinohara K, Wheeler TM, Scardino PT: Detection of microscopic extracapsular extension prior to radical prostatectomy for clinically localized prostate cancer. Br J Urol 1994; 74: 72-79. (Pubitemid 24221530)
16. Fütterer JJ, Barentsz J, Heijmijnk ST: Imaging modalities for prostate cancer. Expert Rev Anticancer Ther 2009; 9: 923-937.
17. Ukimura O: Evolution of precise and multimodal MRI and TRUS in detection and management of early prostate cancer. Expert Rev Med Devices 2010; 7: 541-554.
18. Sauvain JL, Palascak P, Bourscheid D, et al: Value of power Doppler and 3D vascular sonography as a method for diagnosis and staging prostate cancer. Eur Urol 2003; 44: 21-30. (Pubitemid 36741370)
19. Ellegala DB, Leong-Poi H, Carpenter JE, et al: Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha(v)beta3. Circulation 2003; 108: 336-341. (Pubitemid 36899026)
20. Aigner F, Mitterberger M, Rehder P, et al: Status of transrectal ultrasound imaging of the prostate. J Endourol 2010; 24: 685-691.
21. Ohori M, Shinohara K, Wheeler TM, et al: Ultrasonic detection of non-palpable seminal vesicle invasion: a clinicopathological study. Br J Urol 1993; 72: 799-808. (Pubitemid 24000145)
22. Scardino PT, Shinohara K, Wheeler TM, Carter SS: Staging of prostate cancer: value of ultrasonography. Urol Clin North Am 1989; 16: 713-734.
23. Walsh JW, Amendola MA, Konerding KF, Tisnado J, Hazra TA: Computed tomographic detection of pelvic and inguinal lymphnode metastases from primary and recurrent pelvic malignant disease. Radiology 1980; 137: 157-166. (Pubitemid 10002566)
24. Tarcan T, Turkeri L, Biren T, Kullu S, Gurmen N, Akdas A: The effectiveness of imaging modalities in clinical staging of localized prostate cancer. Int Urol Nephrol 1996; 28: 773-779. (Pubitemid 27148027)
25. Yu KK, Hricak H: Imaging prostate cancer. Radiol Clin North Am 2000; 38: 59-85. (Pubitemid 30059006)
26. Burcombe RJ, Ostler PJ, Ayoub AW, Hoskin PJ: The role of staging CT scans in the treatment of prostate cancer: a retrospective audit. Clin Oncol 2000; 12: 32-35. (Pubitemid 30150772)
27. Schnall MD, Pollack HM: Magnetic resonance imaging of the prostate gland. Urol Radiol 1990; 12: 109-114. (Pubitemid 20373321)
28. Zakian KL, Eberhardt S, Hricak H, et al: Transition zone prostate cancer: metabolic characteristics at 1 H MR spectroscopic imaging-initial results. Radiology 2003; 229: 241-247. (Pubitemid 37152131)
29. Akin O, Sala E, Moskowitz CS, et al: Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. Radiology 2006; 239: 784-792. (Pubitemid 43830614)
30. Sala E, Akin O, Moskowitz CS, et al: Endorectal MR imaging in the evaluation of seminal vesicle invasion: diagnostic accuracy and multivariate feature analysis. Radiology 2006; 238: 929-937. (Pubitemid 43289924)
31. Yu KK, Hricak H, Alagappan R, Chernoff DM, Bacchetti P, Zaloudek CJ: Detection of extracapsular extension of prostate carcinoma with endorectal and phased-array coil MR imaging: multivariate feature analysis. Radiology 1997; 202: 697-702. (Pubitemid 27093440)
32. Yu KK, Scheidler J, Hricak H, et al: Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and threedimensional proton MR spectroscopic imaging. Radiology 1999; 213: 481-488. (Pubitemid 29510596)
33. Outwater EK, Petersen RO, Siegelman ES, Gomella LG, Chernesky CE, Mitchell DG: Prostate carcinoma: assessment of diagnostic criteria for capsular penetration on endorectal coil MR images. Radiology 1994; 193: 333-339. (Pubitemid 24338310)
34. Bartolozzi C, Menchi I, Lencioni R, et al: Local staging of prostate carcinoma with endorectal coil MRI: correlation with wholemount radical prostatectomy specimens. Eur Radiol 1996; 6: 339-345. (Pubitemid 126458081)
35. Cornud F, Flam T, Chauveinc L, et al: Extraprostatic spread of clinically localized prostate cancer: factors predictive of pT3 tumor and of positive endorectal MR imaging examination results. Radiology 2002; 224: 203-210. (Pubitemid 34680396)
36. Ikonen S, Karkkainen P, Kivisaari L, et al: Magnetic resonance imaging of clinically localized prostatic cancer. J Urol 1998; 159: 915-919. (Pubitemid 28106556)
37. Ikonen S, Karkkainen P, Kivisaari L, et al: Endorectal magnetic resonance imaging of prostatic cancer: comparison between fatsuppressed T 2-weighted fast spin echo and three-dimensional dual-echo, steady-state sequences. Eur Radiol 2001; 11: 236-241. (Pubitemid 32755442)
38. May F, Treumann T, Dettmar P, Hartung R, Breul J: Limited value of endorectal magnetic resonance imaging and transrectal ultrasonography in the staging of clinically localized prostate cancer. BJU Int 2001; 87: 66-69.
39. Perrotti M, Kaufman RP Jr, Jennings TA, et al: Endo-rectal coil magnetic resonance imaging in clinically localized prostate cancer: is it accurate? J Urol 1996 156 106-109. (Pubitemid 26185650)
40. Presti JC, Hricak H, Narayan PA, Shinohara K, White S, Carroll PR: Local staging of prostatic carcinoma: comparison of transrectal sonography and endorectal MR imaging. AJR Am J Roentgenol 1996; 166: 103-108. (Pubitemid 26010231)
41. Rorvik J, Halvorsen OJ, Albrektsen G, Ersland L, Daehlin L, Haukaas S: MRI with an endorectal coil for staging of clinically localised prostate cancer prior to radical prostatectomy. Eur Radiol 1999; 9: 29-34.
42. Schiebler ML, Yankaskas BC, Tempany C, et al: MR imaging in adenocarcinoma of the prostate: interobserver variation and efficacy for determining stage C disease. AJR Am J Roentgenol 1992; 158: 559-562.
43. Mullerad M, Hricak H, Wang L, Chen HN, Kattan MW, Scardino PT: Prostate cancer: detection of extracapsular extension by genitourinary and general body radiologists at MR imaging. Radiology 2004; 232: 140-146. (Pubitemid 38787829)
44. Wang L, Mullerad M, Chen HN, et al: Prostate cancer: incremental value of endorectal MR imaging findings for prediction of extracapsular extension. Radiology 2004; 232: 133-139. (Pubitemid 38787828)
45. Brajtbord JS, Lavery HJ, Nabizada-Pace F, Senaratne P, Samadi DB: Endorectal magnetic resonance imaging has limited clinical ability to preoperatively predict pT3 prostate cancer. BJU Int 2011;107:1419-1424.
46. Lee SH, Park KK, Choi KH, et al: Is endorectal coil necessary for the staging of clinically localized prostate cancer? Comparison of non-endorectal versus endorectal MR imaging. World J Urol 2010; 28: 667-672.
47. Nogueira L, Wang L, Fine SW et al: Focal treatment or observation of prostate cancer: pretreatment accuracy of transrectal ultrasound biopsy and T 2-weighted MRI. Urology 2010; 75: 472-477.
48. Wang L, Hricak H, Kattan MW, Chen HN, Scardino PT, Kuroiwa K: Prediction of organ confined prostate cancer: incremental value of MRI and MRI spectroscopic imaging to staging nomograms. Radiology 2006; 238: 597-603. (Pubitemid 43134372)
49. Lavery HJ, Brajtbord JS, Levinson AW, Nabizada-Pace F, Pollard ME, Samadi DB: Unnecessary imaging for the staging of low-risk prostate cancer is common. Urology 2011; 77: 274-278.
50. Costello LC, Franklin RB, Feng P: Mitochondrial function, zinc, and intermediary metabolism relationships in normal prostate and prostate cancer. Mitochondrion 2005; 5: 143-153. (Pubitemid 40823303)
51. Kurhanewicz J, Vigneron DB: Advances in MR spectroscopy of the prostate. Magn Reson Imaging Clin N Am 2008; 16: 697-710.
52. Pinto F, Totaro A, Calarco A: Imaging in prostate cancer diagnosis: present role and future perspectives. Urol Int 2011; 86: 373-382.
53. Scheidler J, Hricak H, Vigneron DB, et al: Prostate cancer: localization with threedimensional proton MR spectroscopic imaging-clinicopathologic study. Radiology 1999; 213: 473-480. (Pubitemid 29510595)
54. Nayyar R, Kumar R, Kumar V, Jagannathan NR, Gupta NP, Hemal AK: Magnetic resonance spectroscopic imaging: current status in the management of prostate cancer. BJU Int 2009; 103: 1614-1620.
55. Hricak H: MR imaging and MR spectroscopic imaging in the pre-treatment evaluation of prostate cancer. Br J Radiol 2005; 78:S103-S111. (Pubitemid 43019918)
56. Sciarra A, Panebianco V, Salciciccia S, et al: Modern role of magnetic resonance and spectroscopy in the imaging of prostate cancer. Urol Oncol 2011; 29: 12-20.
57. Engelbrecht MR, Hiusman HJ, Laheij RJ, et al: Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology 2003; 229: 248-254. (Pubitemid 37152132)
58. Futterer JJ, Engelbrecht MR, Huisman HJ, et al: Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers. Radiology 2005; 237: 541-549. (Pubitemid 41507892)
59. Beyersdorff D, Taymoorian K, Knosel T, et al: MRI of prostate cancer at 1.5 T and 3.0 T: comparison of image quality in tumor detection and staging. AJR Am J Roentgenol 2005; 185: 1214-1220.
60. Heijmink SW, Futterer JJ, Hambrock T, et al: Prostate cancer: body-array versus endorectal coil MR imaging at 3T-comparison of image quality localization, and staging performance. Radiology 2007; 244: 184-195. (Pubitemid 46981973)
61. Bloch BN, Furman-Haran E, Helbich TH, et al: Prostate cancer: accurate determination of extracapsular extension with high-spatial resolution dynamic contrast-enhanced and T 2-weighted MR imaging-initial results. Radiology 2007; 245: 176-185. (Pubitemid 47417801)
62. Seitz M, Shukla-dave A, Bjartell A, et al: Functional magnetic resonance imaging in prostate cancer. Eur Urol 2009; 55: 801-814.
63. Qayyum A, Coakley FV, Lu Y, et al: Organconfined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. AJR Am J Roentgenol 2004; 183: 1079-1083. (Pubitemid 44185100)
64. White S, Hricak H, Forstner R, et al: Prostate cancer: effect of postbiopsy hemorrhage on interpretation of MR images. Radiology 1995; 195: 385-390.
65. Park KK, Lee SH, Lim BJ, Kim JH, Chung BH: The effect of the period between biopsy and diffusion-weighted magnetic resonance imaging on cancer staging in localized prostate cancer. BJU Int 2010; 106: 1148-1151.
66. Dickinson L, Ahmed HU, Moore C, et al: The effect of the period between biopsy and diffusion-weighted magnetic resonance imaging on cancer staging in localized prostate cancer. BJU Int 2010; 106: 131-132.
67. Kim CK, Park BK, Kim B: Diffusion-weighted MRI at 3 T for the evaluation of prostate cancer. AJR Am J Roentgenol 2010; 194: 1461-1469.
68. Kim CK, Choi D, Park BK, Kwon GY, Lim HK: Diffusion-weighted MR imaging for the evaluation of seminal vesicle invasion in prostate cancer: initial results. J Magn Reson Imaging 2008; 28: 963-969.
69. Phelps ME: Inaugural article: positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci USA 2000; 97: 9226-9233. (Pubitemid 30627544)
70. Weber G: Enzymology of cancer cells (second of two parts). N Engl J Med 1977; 296: 541-551. (Pubitemid 8038324)
71. Brown RS, Leung JY, Kison PV, Zasadny KR, Flint A, Wahl RL: Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med 1999; 40: 556-565. (Pubitemid 29171796)
72. Delbeke D: Oncological applications of FDG PET imaging. J Nucl Med 1999; 40: 1706-1715. (Pubitemid 29471163)
73. Higashi K, Ueda Y, Yagishita M, et al: FDG PET measurement of the proliferative potential of non-small cell lung cancer. J Nucl Med 2000; 41: 85-92. (Pubitemid 30046688)
74. Reske SN, Grillenberger KG, Glatting G, et al: Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. J Nucl Med 1997; 38: 1344-1348.
75. Su TS, Tsai TF, Chi CW, Han SH, Chou CK: Elevation of facilitated glucose-transporter messenger RNA in human hepatocellular carcinoma. Hepatology 1990; 11: 118-122.
76. Vesselle H, Schmidt RA, Pugsley JM, et al: Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 2000; 6: 3837-3844.
77. Effert PJ, Bares R, Handt S, Wolff JM, Bull U, Jakse G: Metabolic imaging of untreated prostate cancer by positron emission tomography with 18-fluorine-labeled deoxyglucose. J Urol 1996; 155: 994-998.
78. Liu IJ, Zafar MB, Lai YH, Segall GM, Terris MK: Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 2001; 57: 108-111. (Pubitemid 32065829)
79. Turkbey B, Pinto PA, Chyke PL: Imaging techniques for prostate cancer: implications for focal therapy. Nat Rev Urol 2009; 6: 191-203.
80. Bouchelouche K, Oher P: Positron emission tomography/computed tomography of urological malignancies: an update review. J Urol 2008; 179: 34-45. (Pubitemid 350225698)
81. Zeisel SH: Dietary choline: biochemistry, physiology and pharmacology. Annu Rev Nutr 1981; 1: 95-121.
82. Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM: Detection of increased choline compunds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res 2001; 61: 3599-3603. (Pubitemid 32694969)
83. Sutiner E, Nurmi M, Roivainen A, et al: Kinetics of 11 C-choline uptake in prostate cancer: a PET study. Eur J Nucl Med Mol Imaging 2003; 31: 317-324.
84. Husarik DB, Miralbel R, Dubs M, et al: Evaluation of 18 F-choline PET/TC for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 2008; 35: 253-263.
85. Oyama N, Akino H, Suzuki Y, et al: The increased accumulation of 18 F-fluoro-deoxyglucose in untreated prostate cancer. Jpn J Clin Oncol 1999; 29: 623-629.
86. Eschmann SM, Pfannenberg AC, Rieger A, et al: Comparison of 11 C-choline PET/CT and whole body-MRI for staging of prostate cancer. Nuklearmedizin 2007; 46: 161-168. (Pubitemid 47612279)
87. Rinnab L, Blumstein NM, Mottaghy FM, et al: 11 C-choline positron emission tomography/computed tomography and transrectal ultrasonography for staging localized prostate cancer. BJU Int 2007; 99: 1421-1426. (Pubitemid 47164799)
88. Farsad M, Schiavina R, Castellucci P, et al: Detection and localization of prostate cancer: correlation of 11 C-choline PET/CT with histopathologic step-section analysis. J Nucl Med 2005; 46: 1642-1649. (Pubitemid 46211588)
89. Martorana G, Schaivina R, Cort B, et al: 11 Ccholine positron emission tomography/computed tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. J Urol 2006; 176: 954-960. (Pubitemid 44142558)
90. Beheshti M, Imamovic L, Broinger G, et al:
91. F-choline PET/TC in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study on 130 patients. Radiology 2010; 254: 925-933.
92. O'Dowd GJ, Veltri RW, Orozco R, Miller MC, Oesterling JE: Update on the appropriate staging evaluation for newly diagnosed prostate cancer. J Urol 1997; 158: 687-698.
93. Partin AW, Kattan MW, Subong EN, et al: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update. JAMA 1997; 277: 1445-1451. (Pubitemid 27208886)
94. Ohori M, Kattan MW, Koh H: Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol 2004; 171: 1844-1849. (Pubitemid 38501019)
95. Pouliot F, Johnson M, Wu L: Non-invasive molecular imaging of prostate cancer lymph nodes metastases. Trends Mol Med 2009; 15: 254-260.
96. Hövels AM, Heesakkers RA, Adang EM, et al: The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 2008; 63: 387-395.
97. Harisinghani MG, Barentsz J, Hahn PF, et al: Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003; 348: 2491-2499. (Pubitemid 36706536)
98. Zahee A, Cho SY, Pomper MG: New agents and techniques for imaging prostate cancer. J Nucl Med 2009; 50: 1387-1390.
99. Thoeny HC, Triantafyllou M, Birkhaeuser FD, et al: Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal sized nodes of bladder and prostate cancer patients. Eur Urol 2009; 55: 761-769.
100. 11 C-choline PET. J Nucl Med 2003; 44: 331-335. (Pubitemid 39586006)
101. Schiavina R, Scattoni V, Castellucci P, et al: (11)C-choline positron emission tomography/computerized tomography for preoperative lymph node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol 2008; 54: 392-401.
102. 18 F-choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology 2010; 254: 925-933.
103. Steuber T, Scholomm T, Heinzer H, et al: [F(18)]-fluoroethylcholine combined inline PET-TC scan for detection of lymph node metastasis in high risk prostate cancer patients prior to radical prostatectomy: preliminary results from a prospective histology-based study. Eur J Cancer 2010; 2: 449-455.
104. Poulsen MH, Bouchelouche K, Gerke O, et al: [F(18)]-fluorocholine positron-emission/computed tomography for lymph node staging of patients with prostate cancer: preliminary results of a prospective study. BJU Int 2010; 106: 639-643.
105. Budiharto T, Joniau S, Lerut E, et al: Prospective evaluation of (11)C-choline positron emission tomography and diffusionweighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases. Eur Urol 2011; 60: 125-130.
106. Thurairaia R, McFarlane J, Traill Z, Persad R: State-of-the-art approaches to detecting early bone metastasis in prostate cancer. BJU Int 2004; 94: 268-271. (Pubitemid 39120162)
107. European Association of Urology Guidelines 2010. http://www.uroweb.org/ guidelines/.
108. Oesterling JE: Using PSA to eliminate the staging radionuclide bone scan: significant economic implications. Urol Clin North Am 1993; 20: 705-711. (Pubitemid 24141164)
109. O'Dowd GJ, Veltri RW, Orozco R, Miller MC, Oesterling JE: Update on the appropriate staging evaluation for newly diagnosed prostate cancer. J Urol 1997; 158: 687-698.
110. Messiou C, Cook G, de Souza NM: Imaging metastatic bone disease from carcinoma of the prostate. Br J Cancer 2009; 101: 1225-1232.
111. Lawrentschuk N, Davis ID, Bolton DM, Scott AM: Diagnostic and therapeutic use of radioisotopes for bony disease in prostate cancer: current practise. Int J Urol 2007; 14: 89-95. (Pubitemid 46121943)
112. Pollen JJ, Witztum KS, Ashburn WL: The flare phenomenon on radionuclide bone scan in metastatic prostate cancer. AJR Am J Roentgenol 1984; 142: 773-776. (Pubitemid 14166610)
113. Schneider JA, Divgi CR, Scott AM, et al: Flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer. J Nucl Med 1994; 35: 1748-1752. (Pubitemid 24346792)
114. Taoka T, Mayr NA, Lee HJ, et al: Factors influencing visualization of vertebral metastases on MR imaging versus bone scintigraphy. AJR Am J Roentgenol 2001; 176: 1525-1530. (Pubitemid 32510275)
115. Leucovet FE, Geukens D, Stainer A, et al: Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol 2007; 25: 3281-3287. (Pubitemid 47325613)
116. Gutzeit A, Doert A, Froehlich JM, et al: Comparison of diffusion-weighted whole body MRI and skeletal scintigraphy for the detection of bone metastases in patients with prostate or breast carcinoma. Skeletal Radiol 2010; 39: 333-343.
117. Reischauer C, Froelich JM, Koh DM, et al: Bone metastases from prostate cancer: assessing treatment response by using diffusion-weighted imaging and functional diffusion maps-initial observations. Radiology 2010; 257: 523-531.
118. Nozaki T, Yusuda K, Akashi T, et al: Usefulness of single photon emission computed tomography imaging in the detection of lumbar vertebral metastases from prostate cancer. Int J Urol 2008; 15: 516-519. (Pubitemid 351713180)
119. Delpassand ES, Garcia JR, Bhadkamar V, Podoloff DA: Value of SPECT imaging of the thoracolumbar spine in cancer patients. Clin Nucl Med 1995; 20: 1047-1051.
120. Even-Sapir E, Martin RH, Barnes DC, Pringle CR, Iles SE, Mitchell MJ: Role of SPECT in differentiating malignant from benign lesions in the lower thoracic and lumbar vertebrae. Radiology 1993; 187: 193-198. (Pubitemid 23097884)
121. Helyar V, Mohan HK, Barwick T, et al: The added value of multislice SPECT/CT in patients with equivocal bony metastasis from carcinoma of the prostate. Eur J Nucl Med Mol Imaging 2010; 37: 706-713.
122. Morris MJ, Akhurst T, Osman I, et al: Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 2002; 59: 913-918. (Pubitemid 34522186)
123. Akin O, Hricak H: Imaging of prostate cancer. Radiol Clin North Am 2007; 45: 207-222. (Pubitemid 44854046)
124. Schoder H, Larson SM: Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 2004; 34:274-292. (Pubitemid 39365998)
125. Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA: Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 2001; 42: 432-445. (Pubitemid 32207394)
126. Nunez R, Macapinlac HA, Yeung HW, et al: Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med 2002; 43: 46-55. (Pubitemid 34101187)
127. Fuccio C, Castellucci P, Schiavina R, et al: Role of 11-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy. Ann Nucl Med 2010; 24: 485-492.
128. Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I: The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single-and multi-field-of-view SPECT, 18 F-fluoride PET, and 18 F-fluoride PET/CT. J Nucl Med 2006; 47: 287-297. (Pubitemid 46780894)
129. Withofs N, Grayet B, Tancredi T, et al: 18Ffluoride PET/TC for assessing bone involvement in prostate and breast cancer. Nucl Med Commun 2011; 32: 168-176.
130. McCarthy M, Siew T, Campbell A, et al: 18 Ffluoromethylcholine (FCH) PET imaging in patients with castration-resistant prostate cancer: prospective comparison with standard imaging. Eur J Nucl Med Mol Imaging 2011; 38: 14-22.
131. 11 Ccholine. J Nucl Med 2001; 52: 81-89.